Mark C. Markowski

Sidney Kimmel Comprehensive Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial”.

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Nature Communications(2024)10.1038/s41467-023-44514-2

N/A

1.3DataRank · unranked

49 citations

Mary‐Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi +15 more

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy

European Journal of Cancer(2020)10.1016/j.ejca.2020.11.043

N/A

1.2DataRank · unranked

47 citations

Hao Wang, Su J. Lim ScM, Irina Rifkind, Nduku Ngomba, John T. Isaacs +10 more

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BMC Cancer(2020)10.1186/s12885-020-07000-2

N/A

1.1DataRank · unranked

32 citations

Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan +26 more

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited

European Urology(2021)10.1016/j.eururo.2020.12.040

N/A

0.692DataRank · unranked

100 citations

Kim Van der Eecken, Ryan Phillips, Neil R. Parikh, Pedro Isaacsson Velho, Tamara L. Lotan +19 more

TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations

(2024)10.1093/oncolo/oyae120

N/A

0.687DataRank · unranked

14 citations

Cora N. Sternberg, Hao Wang, Tingchang Wang, Laura Linville, Catherine H. Marshall +5 more

Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

Cancer Research(2021)10.1158/0008-5472.can-20-3607

N/A

0.587DataRank · unranked

49 citations

Janet Mendonca, Olutosin Owoyemi, Kavya Boyapati, Naiju Thomas, Suthicha Kanacharoen +20 more

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0225

N/A

0.554DataRank · unranked

18 citations

Marianna Zahurak, Adel Mandl, Nicole A. Metri, Aliya Lalji, Elisabeth I. Heath +18 more

Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F‐DCFPyL test–retest cohort

The Prostate(2023)10.1002/pros.24483

N/A

0.406DataRank · unranked

14 citations

Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Alekandser Kosmala, Markus Essler +14 more

Test–retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer

The Prostate(2023)10.1002/pros.24577

N/A

0.263DataRank · unranked

4 citations

Susanne Lütje, Bilêl Habacha, Lena Bundschuh, Takahiro Higuchi, Andreas K. Buck +12 more

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5087

N/A

0.241DataRank · unranked

4 citations

Benjamin A. Teply, Su Jin Lim, Hao Wang, Shifeng Mao, William Kevin Kelly +10 more

Clinical management and outcomes of HIV-positive patients newly diagnosed with prostate cancer: a single institution experience

Prostate Cancer and Prostatic Diseases(2022)10.1038/s41391-022-00586-7

N/A

0.104DataRank · unranked

1 citations

Filip Pirsl, Jeanne Keruly, Geetanjali Chander, Richard D. Moore, Bryan Lau +2 more

RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5576

N/A

0.104DataRank · unranked

1 citations

Hao Wang, Michael T. Schweizer, Michael A. Carducci, Channing J. Paller, Benjamin A. Teply +5 more

Data from Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

(2023)10.1158/0008-5472.c.6513589.v1

N/A

0DataRank · unranked

0 citations

Janet Mendonca, Olutosin Owoyemi, Kavya Boyapati, Naiju Thomas, Suthicha Kanacharoen +20 more

1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2781

N/A

0DataRank · unranked

0 citations

M.L. Zahurek, Adel Mandl, Michelle A. Rudek, Elisabeth I. Heath, Catherine H. Marshall +13 more

Bipolar androgen therapy (BAT): A patient's guide

The Prostate(2022)10.1002/pros.24328

N/A

0DataRank · unranked

27 citations

Emmanuel S. Antonarakis, Mark C. Markowski, Samuel R. Denmeade

Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer

European Urology Oncology(2024)10.1016/j.euo.2024.11.009

N/A

0DataRank · unranked

13 citations

Yi Ren, Meghan Tierney, Trevor J. Royce, Rikiya Yamashita, Danielle Croucher +13 more

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer

The Prostate(2024)10.1002/pros.24712

N/A

0DataRank · unranked

17 citations

Lukasz P. Gondek, В. Даниэльс, Changxue Lu, Sergiu Paşca, Jiajun Xie +7 more

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

The Prostate(2020)10.1002/pros.23955

N/A

0DataRank · unranked

37 citations

Eugene Shenderov, Mario A. Eisenberger, Sushant K. Kachhap, Drew M. Pardoll, Samuel R. Denmeade +2 more

Prostate cancer androgen receptor activity dictates efficacy of Bipolar Androgen Therapy

medRxiv(2022)10.1101/2022.04.26.22274275

N/A

0DataRank · unranked

4 citations

Rajendra Kumar, David E. Sanin, Elizabeth A. Thompson, Dina Rosen, Susan L. Dalrymple +20 more

Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma

Frontiers in Oncology(2024)10.3389/fonc.2024.1432286

N/A

0DataRank · unranked

4 citations

Anand K Thotakura, Suresh Alati, Alla Lisok, Zirui Jiang, Vanessa F. Merino +12 more

Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images

Modern Pathology(2023)10.1016/j.modpat.2023.100247

N/A

0DataRank · unranked

27 citations

Lia DePaula Oliveira, Adrianna A. Mendes, Oluwademilade Dairo, Onur Ertunç, İbrahim Kulaç +17 more

MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression

JCI Insight(2023)10.1172/jci.insight.169868

N/A

0DataRank · unranked

17 citations

Qizhi Zheng, Jessica Hicks, Levent Trabzonlu, Büşra Özbek, Tracy Jones +13 more

MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.20.529259

N/A

0DataRank · unranked

5 citations

Qizhi Zheng, Jessica Hicks, Levent Trabzonlu, Büşra Özbek, Tracy Jones +13 more